This date, April 11, marks the birthday of Dr. James Parkinson, the first surgeon to observe and characterize the disease now known as Parkinson’s disease. In his paper offered in 1817 and titled, “An Essay on the Shaking Palsy”, he named what he observed as “paralysis agitan”. Eventually, the affliction became known as Parkinson’s disease (PD).
PD is a long-term degenerative disease of the central nervous system. It mainly affects the motor system and its symptoms usually have slow-onset. In early stages, the disease is characterized by shaking, slow movement, difficulty in walking, and rigidity. In time, thinking and behavioral problems may occur. Advanced stages of the disease bring dementia.
There is no cure for PD. The loss of motor function results from cell death in the midbrain region known as the substantia nigra. This translates into low dopamine levels in these areas of the brain causing poor control of the musculature.
World-wide, over 10 million people are afflicted with PD and the yearly mortality rate from this disease is greater than 100,000, globally. PD is more common in people over the age of 60, (where approximately, 1% of this age group is affected), and appears more common in males than females.
International Stem Cell Corporation (ISCO), a company based in Carlsbad, CA, has devoted many years of research to improve this terrible disease. The Company has developed a unique method of creating human neural stem cells which when introduced into the brain, promote the recovery of dopaminergic neurons, the brain cells that are originally affected and cause the disease symptoms. ISCO’s preclinical studies showed that the administration of these neural stem cells were safe and improved motor symptoms while increasing dopamine concentrations. To date, 3 of the planned total of 12 patients, have entered the clinical trial and have received neural stem cells. At this point in time, all patients have been discharged from their hospital settings and are observed to be meeting clinical expectation.
Lifeline Skin Care (LSC), is a subsidiary of ISCO. LSC uses the extracts from human stem cells, (produced by ISCO), and developed for the skin in order to improve the signs of aging. The latest technology being used to advance a cure for PD is now available for the skin in a line of products produced by Lifeline Skin Care. The profits derived from the sale of these skin care products go directly to ISCO in order to fund the development of a therapy for PD.
Lifeline Skin Care has developed a line of products that treat the different areas of our skin. All of these serums contain human stem cell extracts. These human stem cell extracts stimulate skin cells to produce more collagen and elastin which naturally decrease with age. As a result, clinical observations have demonstrated that skin treated with serums containing the human stem cell extracts appear younger than the subject’s true chronological age.
As remarkable as these human stem cell extracts are, they would not be effective if not for a method of preserving them and allowing their absorption into the skin, itself. Lifeline has developed a method of micro encapsulating these extracts inside microspheres in order to preserve and help promote absorption into the skin and to the very depth and level where activity is required.
The ability to reduce the signs of aging is now possible using ISCO’s stem cell technology. Lifeline Skin Care is proud to offer this patented and state-of-the-art technology to the public and in return, be able to contribute to the therapy for Parkinson's Disease.
To learn more, please visit International Stem Cell Corporation.